Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis
Open Access
- 13 September 2026
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11320-11327
Abstract
Aims: While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis). Given similarities in pathophysiology between CKD in T1DM and T2DM, we conducted a systematic review and meta‐analysis evaluating sodium–glucose cotransporter‐2 inhibitors (SGLT‐2is), mineralocorticoid receptor antagonists (MRAs) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on kidney function, albuminuria and safety outcomes. Materials and Methods: We searched Medline, EMBASE, Cochrane CENTRAL, CINAHL, Global Health, LILACS and Scopus from inception until 11 April 2025, for randomised controlled trials (RCTs) evaluating RASi, MRAs, GLP‐1RAs and SGLT‐2is on change in urine albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in adults (age ≥ 18) with T1DM. Results: A total of 7151 unique records were identified and 41 RCTs were included in the meta‐analysis. No RCTs evaluating nsMRAs or MRAs met our inclusion criteria. Treatment with SGLT‐2i or RASi was associated with a 45% reduction in UACR versus placebo (GMR = 0.55; 95% CI: 0.32–0.94). No difference in the annual rate of eGFR change was observed across drug classes compared to placebo (mean difference 1.16 mL/min/1.73 m 2 /year; 95% CI: −0.38 to 2.70). Treatment was associated with a higher risk of hypoglycaemia (RR = 1.03; 95% CI: 1.01–1.05) and DKA (RR = 1.97; 95% CI: 1.33–2.93). Conclusions: In patients with T1DM, the pooled analysis showed a reduction in UACR overall, but that this appeared to be driven predominantly by the SGLT‐2i studies, with limited and non‐significant evidence in the RAS inhibitor subgroup. Dedicated RCTs in the T1DM population could help establish the efficacy and safety of these different drug classes. Trial Registration: PROSPERO registration: CRD420261352699.Keywords
Funding Information
- Bayer
This publication has 18 references indexed in Scilit:
- Impact of Body Mass Index Variability on Kidney Disease Progression in a Large Type 1 Diabetes CohortDiabetes/Metabolism Research and Reviews, 2026
- Finerenone in Type 1 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2026
- Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney diseaseExpert Review of Clinical Immunology, 2025
- Prevalence and severity of chronic kidney disease in a population with type 1 diabetes from a United States health system: a real-world cohort studyThe Lancet Regional Health - Americas, 2025
- Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetesMetabolism, 2023
- The many faces of hypertension in individuals with type 1 diabetesDiabetes Research and Clinical Practice, 2023
- The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetesNephrology Dialysis Transplantation, 2022
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 DiabetesNew England Journal of Medicine, 2017
- NoticeKidney International Supplements, 2013
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993